ANI Pharmaceuticals Posts Record 2025 Results on Rare Disease Growth

ANI Pharmaceuticals ( (ANIP) ) has provided an update.

ANI Pharmaceuticals reported record net revenues of $247.1 million for the fourth quarter and $883.4 million for full-year 2025, representing year-over-year growth of 29.6% and 43.8%, respectively. The company also delivered record adjusted non-GAAP EBITDA of $65.4 million in the quarter and $229.8 million for the year, alongside GAAP net income available to common shareholders of $27.5 million in the quarter and $77.2 million for 2025.

Growth was driven primarily by the Rare Disease segment, which generated quarterly and full-year net revenue of $131.3 million and $422.6 million, up 50.8% and 84.1% from the prior year, with Purified Cortrophin Gel contributing $111.4 million in quarterly sales and $347.8 million for the year. Newly reported contributions from ILUVIEN and YUTIQ added $19.8 million in fourth-quarter revenue and $74.9 million for 2025, supporting both top- and bottom-line expansion as the company reaffirmed its 2026 financial guidance.

Earnings performance strengthened with quarterly diluted GAAP income per share of $1.18 and adjusted non-GAAP diluted EPS of $2.33, while full-year diluted GAAP EPS reached $3.32 and adjusted non-GAAP diluted EPS was $7.89. The robust results highlight ANI Pharmaceuticals’ growing scale in rare disease and generics and underscore management’s confidence in sustaining momentum into 2026, which may bolster investor sentiment and solidify the firm’s competitive positioning in its targeted markets.

The most recent analyst rating on (ANIP) stock is a Buy with a $121.00 price target. To see the full list of analyst forecasts on ANI Pharmaceuticals stock, see the ANIP Stock Forecast page.

Spark’s Take on ANIP Stock

According to Spark, TipRanks’ AI Analyst, ANIP is a Neutral.

ANIP scores above average primarily on improving financial performance (profitability and strong free cash flow) and a bullish earnings-call backdrop (raised guidance and strong Rare Disease growth). These positives are tempered by weak technicals (below key moving averages with negative MACD) and a high P/E with no dividend support.

To see Spark’s full report on ANIP stock, click here.

More about ANI Pharmaceuticals

ANI Pharmaceuticals, Inc. is a U.S.-based specialty pharmaceutical company listed on the Nasdaq Stock Market. The company focuses on rare disease therapies and generic drug products, with key revenue drivers including Purified Cortrophin Gel and ophthalmic products ILUVIEN and YUTIQ targeting niche, high-value patient populations.

Average Trading Volume: 433,695

Technical Sentiment Signal: Buy

Current Market Cap: $1.72B

Learn more about ANIP stock on TipRanks’ Stock Analysis page.